The arrival of Retatrutide ZPHC, at a dosage of 120mg, is sparking considerable interest within the medical community. This innovative dual GIP and GLP-1 agonist medication appears to offer impressive improvements in fat reduction compared to previous therapies. Early patient studies have indicated marked decreases in weight , possibly representing